What the trial was testing
The MT-12 enrolled 1,460 patients with allergic rhinitis. The study was sponsored by ALK-Abelló and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
22% relative reduction in combined symptom score on the dust mite tablet.
The Lancet Regional Health - Europe · 2025 · NCT04145219
These findings — that in combined rhinitis symptoms on the dust mite tablet vs. inactive tablet — were published in the The Lancet Regional Health - Europe and represent the headline result of the study.
Researchers tracked outcomes across 1,460 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with allergic rhinitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
House dust mite sublingual tablets (Odactra) are FDA-approved for adults but the pediatric indication is still under review in the U.S. as of early 2026. The tablet is approved in many other countries for children. Ask an allergist about access or oral allergy drops as alternatives.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open allergic rhinitis trials
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.
Implementation of an Allergic Rhinitis Severity Questionnaire in ENT Consultations
Allergic rhinitis is a very common condition (affecting 1 in 5 people in Europe) and a costly one for society (direct and indirect costs). Symptoms vary depending on the time of year, and treatments are primarily symptomatic, with follow-up in ENT consultations. Scientific societies (EAACI, FDA, EMA) recommend using a universal tool (severity score) (the CSMS score, SCST in French) to monitor severity and follow-up, and to obtain consistent data that can be extrapolated to other scientific data (meta-analyses). Therefore, investigators in the ENT department use this SCST score (as well as others such as the SNOT 22 score) to assess the severity of allergic rhinitis in our patients and its progression. Tbe investigators wish to confirm the acceptability of this tool for patients, and the statistical value of its properties.